Creating value in medtech has become a challenge, particularly for large diversified companies. As an example, the top 30 cross-category companies in the industry have underperformed the S&P over one-, three-, and five-year periods.
To read the article, see “Accelerating growth in medtech: The next surge in portfolio moves,” May 10, 2022.